In the last six weeks, I’ve signed out seven oral mucosal biopsies with lichenoid interface mucositis where the clinical impression was OLP, but medication histories later revealed recent starts on ACE inhibitors or NSAIDs; DIF was negative or only weakly granular in most. Are others seeing this drift, and are you weighting medication timelines and deeper perivascular inflammation before committing to OLP on the report?
I use a free Google Form QR check-in that asks walk-ins one question and slots them into the next 10-minute demo, which keeps the desk moving during “busy times” and alerts the right rep. Small caveat: print a backup sign-in sheet for Wi‑Fi hiccups.
Seeing the same drift, @OP; my quick fix was adding a “start date” line for every systemic med on the requisition and, when lesions are patchy/asymmetric with deep perivascular cuffing and a few eos, I push drug as top line and suggest a 4–6 week dechallenge if the prescriber’s game. Caveat: cinnamon mouthwash/gum or metal contact can mimic this, and a true OLP can be DIF-light, so I still ask for HCV when the story’s fuzzy; concise refresher: https://www.pathologyoutlines.com/topic/oralcavitylichenplanus.html. At this point the med list is my new special stain.
Lately I flag any case with a new ACEi/NSAID in the prior 4–8 weeks as ‘LDR favored’ when I see scattered eosinophils, focal parakeratosis, and deeper perivascular cuffing. I add a note requesting a trial switch/hold and warn that lesions can lag 6–12 weeks after stopping and DIF may be bland. Caveat: if it’s perfectly symmetric with crisp Wickham change and no eos, I still call OLP despite the timeline.
Quick example: in the last six weeks I had two “OLP” biopsies flip to drug when we checked refill dates — new lisinopril and naproxen about 4 weeks prior, DIF faint to negative… I now drop a stock line, “please review new systemic meds within the last 2 months and consider a 6–8 week dechallenge,” and I’ll ring the prescriber; one caveat, I’ve seen true OLP with weak DIF too, so I lean on suprabasal dyskeratosis and segmental involvement more than the stain. @dora_p92 makes a fair point, but what really flags me is keratinocyte death above the basal layer rather than how deep the infiltrate runs.